NasdaqGS:GHHealthcare
FDA Approves New Colorectal Cancer Use For Guardant360 Might Change The Case For Investing In Guardant Health (GH)
Earlier this week, Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer patients eligible for treatment with BRAFTOVI (encorafenib) plus cetuximab and chemotherapy.
This marks the test’s first approval in colorectal cancer and its 25th companion diagnostic indication overall, underscoring the expanding role of non-invasive genomic profiling in tailoring treatment when tissue samples...